Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 17, 2011, Pages 7154-7159

  Hamzah, Juliana ^a   Kotamraju, Venkata R ^a   Seo, Jai W ^b   Agemy, Lilach ^a   Fogal, Valentina ^c,d   Mahakian, Lisa M ^b   Peters, David ^a   Roth, Lise ^a   Gagnon, M Karen J ^b   Ferrara, Katherine W ^b   Ruoslahti, Erkki ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

^c BURNHAM INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cell penetrating peptide; In vivo imaging; p32 gC1qR hyaluronic acid binding protein1; Plaque associated macrophages

Indexed keywords

APOLIPOPROTEIN E; BENZOIC ACID DERIVATIVE; CYCLOPEPTIDE; CYSTEINYLARGINYLGLUTAMYLLYSYLALANINE; FIBRIN; FIBRONECTIN; FLUORESCEIN; FLUOROBENZENE; LYP 1 PEPTIDE; PENTAPEPTIDE; PROTEIN P32; RECEPTOR PROTEIN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL HOMING; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TARGETING; FEMALE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DRUG DELIVERY SYSTEMS; FEMALE; FERRIC COMPOUNDS; MICE; MICE, MUTANT STRAINS; NANOPARTICLES; OLIGOPEPTIDES; PEPTIDES, CYCLIC;

MUS;

EID: 79955552146     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1104540108     Document Type: Article

References (36)

1. Ruoslahti E, Bhatia SN, Sailor MJ (2010) Targeting of drugs and nanoparticles to tumors. J Cell Biol 188:759-768.
2. Nahrendorf M, et al. (2008) Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 117:379-387.
3. Jaffer FA, et al. (2008) Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation 118:1802-1809.
4. Pasqualini R, Ruoslahti E (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380:364-366. (Pubitemid 26097120)
5. Kelly KA, Nahrendorf M, Yu AM, Reynolds F, Weissleder R (2006) In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Mol Imaging Biol 8:201-207.
6. Nahrendorf M, et al. (2006) Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 114: 1504-1511. (Pubitemid 44527006)
7. Nahrendorf M, et al. (2009) 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging 2:1213-1222.
8. Liu C, Bhattacharjee G, Boisvert W, Dilley R, Edgington T (2003) In vivo interrogation of the molecular display of atherosclerotic lesion surfaces. Am J Pathol 163:1859-1871.
9. Nicol CG, et al. (2009) Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature. FEBS Lett 583:2100-2107.
10. Peters D, et al. (2009) Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci USA 106:9815-9819.
11. Hong HY, et al. (2008) Phage display selection of peptides that home to atherosclerotic plaques: IL-4 receptor as a candidate target in atherosclerosis. J Cell Mol Med 12(5B):2003-2014.
12. Simberg D, et al. (2007) Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci USA 104:932-936. (Pubitemid 46154714)
13. Wilson HM, Barker RN, Erwig LP (2009) Macrophages: Promising targets for the treatment of atherosclerosis. Curr Vasc Pharmacol 7:234-243.
14. Fogal V, Zhang L, Krajewski S, Ruoslahti E (2008) Mitochondrial/cell- surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res 68: 7210-7218.
15. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E (2002) A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 8:751-755. (Pubitemid 34778730)
16. Peerschke EI, et al. (2004) Expression of gC1q-R/p33 and its major ligands in human atherosclerotic lesions. Mol Immunol 41:759-766. (Pubitemid 38953633)
17. Laakkonen P, et al. (2004) Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci USA 101:9381-9386. (Pubitemid 38812883)
18. Agemy L, et al. (2010) Nanoparticle-induced vascular blockade in human prostate cancer. Blood 116:2847-2856.
19. Gagnon MK, et al. (2009) High-throughput in vivo screening of targeted molecular imaging agents. Proc Natl Acad Sci USA 106:17904-17909.
20. Nakano T, et al. (2005) Angiogenesis and lymphangiogenesis and expression of lymphangiogenic factors in the atherosclerotic intima of human coronary arteries. Hum Pathol 36:330-340. (Pubitemid 40591802)
21. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (2009) C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA 106:16157-16162.
22. Sugahara KN, et al. (2010) Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328:1031-1035.
23. Sugahara KN, et al. (2009) Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16:510-520.
24. Muta T, Kang D, Kitajima S, Fujiwara T, Hamasaki N (1997) p32 protein, a splicing factor 2-associated protein, is localized in mitochondrial matrix and is functionally important in maintaining oxidative phosphorylation. J Biol Chem 272:24363-24370. (Pubitemid 27418642)
25. Dedio J, Jahnen-Dechent W, Bachmann M, Müller-Esterl W (1998) The multiligandbinding protein gC1qR, putative C1q receptor, is a mitochondrial protein. J Immunol 160:3534-3542. (Pubitemid 28164749)
26. Fogal V, et al. (2010) Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol Cell Biol 30: 1303-1318.
27. Hosszu KK, Santiago-Schwarz F, Peerschke EI, Ghebrehiwet B (2010) Evidence that a C1q/C1qR system regulates monocyte-derived dendritic cell differentiation at the interface of innate and acquired immunity. Innate Immun 16:115-127.
28. Briley-Saebo KC, et al. (2011) Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidationspecific epitopes. J Am Coll Cardiol 57:337-347.
29. Morris JB, et al. (2008) p38MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment. Arterioscler Thromb Vasc Biol 28:265-271. (Pubitemid 351161198)
30. Guhlke S, Wester HJ, Bruns C, Stöcklin G (1994) (2-[18F] fluoropropionyl-(D)phe1)- octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: Synthesis, radiolabeling, in vitro validation and biodistribution in mice. Nucl Med Biol 21:819-825.
31. Jarrett BR, Correa C, Ma KL, Louie AY (2010) In vivo mapping of vascular inflammation using multimodal imaging. PLoS ONE 5:e13254.
32. Park JH, et al. (2010) Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci USA 107:981-986.
33. Sutcliffe-Goulden JL, et al. (2002) Rapid solid phase synthesis and biodistribution of 18F-labelled linear peptides. Eur J Nucl Med Mol Imaging 29:754-759.
34. Reddick RL, Zhang SH, Maeda N (1994) Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb 14:141-147.
35. Maeda N, et al. (2007) Anatomical differences and atherosclerosis in apolipoprotein E-deficient mice with 129/SvEv and C57BL/6 genetic backgrounds. Atherosclerosis 195:75-82. (Pubitemid 47561948)
36. Uchida M, et al. (2011) Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. ACS Nano, in press.